Actualités

Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.

JNJ and AbbVie both beat revenue expectations in Q1 2026, yet their strategies could not look more different, and which playbook actually wins depends entirely on what kind of investor you are.

A dividend cut does not announce itself in advance, but the warning signs appear in the financials long before management steps up to the microphone. Morningstar's index strategists built a three-signal framework to spot the vulnerable payers before the bad news drops.

U. S. stock futures traded little changed on Friday as investors paused after Thursday’s technology-led rally, shifting their attention toward next week’s corporate earnings reports and key inflation releases.

Beyond analysts' top-and-bottom-line estimates for Johnson & Johnson (JNJ), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

A long-term care policy does not just protect against a future care bill. It also creates a premium bill that may have to be paid for decades. A healthy 55-year-old buying meaningful inflation protection can face annual premiums in the low-to-mid thousands, and a 55-year-old couple can easily cross $5,000 combined. The planning question is: ... What Would It Take to Permanently Cover Long-Term Care Insurance Premiums?

This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.

An investor who bought Microsoft (NASDAQ:MSFT) ten years ago paid closer to $50 per share than $45. Those shares now pay $3.64 per year in dividends, based on Microsoft’s current $0.91 quarterly payout. That is a yield on cost of roughly 7%, even though the stock’s current yield is about 1%. The starting yield helped, ... The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet

Thank you very much for attending! Question Answer Lots of reverb! Close zoom down and re-open the webinar Interesting issue of whether bio/medical, software, financials, small caps are just a rotation play versus an enduring trend, and whether AI is going to trend back up or just chop around Great Q. Might be yes and yes. Thx Cheers Bill, thank...

Twelve thousand dollars a month sounds like a round number, but it carries weight. It works out to $144,000 a year, a little more than twice the U.S. per capita disposable personal income of $68,391 reported for the first quarter of 2026. Replacing that with portfolio income, rather than a paycheck, is a math problem ... How Large Does Your Portfolio Need to Be to Generate $12,000 a Month?

A sharp sector rotation has knocked down some of the market’s steadiest names, and Jim Cramer told CNBC viewers this week that the dislocations are exactly the kind of setup patient investors should welcome. On the July 6 episode of Mad Money, Cramer framed the pullback this way: “These rotations create dislocations that seem to ... Jim Cramer: Buy the Dip on These 3 Stocks Now

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Fundstrat’s Tom Lee returned to CNBC’s Morning Call Sheet on Thursday, July 9, alongside JonesTrading’s Mike O’Rourke and Vital Knowledge’s Adam Crisafulli, to discuss a market that is simultaneously celebrating the AI build-out while rotating into value and defensive names. Lee argued: “AI is probably one of the most important structural stories in our lifetime.” ... Fundstrat’s Tom Lee: AI Is a Once in a Lifetime Story – Why Easing Inflation in H2 2026 Could Fuel the Next Rally

Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.

If you hold shares in this medical device maker, you are already carrying the full weight of a sizable potential swing that the market is pricing for the year ahead.

The options market has priced a sizable range of outcomes for the surgical robotics leader, and if you hold the shares, you are already carrying that full exposure.

AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.

The retirement income math often starts in the wrong place. A retiree who wants $60,000 a year might divide that figure by a portfolio yield and assume the highest yield is the most efficient path: about $1.71 million at 3.5%, $857,000 at 7%, or $500,000 at 12%. On day one, the 12% portfolio looks like ... Why the Best Retirement Paycheck May Start Smaller Than You Expect

The math is simple. A $1 million portfolio generating $100,000 in annual income requires a blended yield of 10%. That is achievable today, but only by leaning hard into the aggressive end of the dividend spectrum. The question this article answers: what does that portfolio actually look like, and what happens when the highest yielder ... How a $1 Million Dividend Portfolio Can Generate $100,000 Annually

Johnson & Johnson (NYSE:JNJ) was among Jim Cramer’s stock calls on Mad Money, as he highlighted the AI opportunities in neoclouds. Cramer was bullish on the stock and expects positive developments for the company, as he stated: You’re going to see some massive moves in real time for no reason whatsoever. Why do we care […]

A $60,000 retirement paycheck sounds like a single target, but a portfolio can produce it in very different ways. A lower-yield portfolio demands more capital upfront but may give the income room to grow. A high-yield portfolio can shrink the capital requirement, but it usually asks the investor to accept more credit risk, distribution risk, ... The Retirement Portfolio That Pays You Without Demanding Constant Attention

Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.

A share of Johnson & Johnson (NYSE: JNJ) paid $0.25 per quarter in dividends in 1999. That same share pays $1.34 per quarter in 2026. The stock price has moved through plenty of cycles since then, but the income stream alone has more than quintupled without the investor doing anything except holding. That trajectory is ... The Case For Buying Smaller Dividends That Grow Faster

Johnson & Johnson recently received U.S. FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, an ablation catheter that can deliver both radiofrequency and pulsed field energy through a single device, integrated with the CARTO mapping ecosystem, with U.S. procedures set to begin following a phased commercial rollout this summer. This dual-energy, single-catheter approach could deepen Johnson & Johnson’s position in advanced electrophysiology by simplifying workflows for...

Johnson & Johnson (JNJ) closed at $263.4 in the latest trading session, marking a -1.44% move from the prior day.

Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri

If you hold shares in this surgical robotics leader, you are already carrying a sizable two-sided risk, whether you trade options or not.

For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th

Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.